Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant’s $2.4bn acquisition of Fusion Pharmaceuticals.
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
- Update Date：
- Post Date：
- Tags
